丁香园 | 丁香通 | 人才 | 会议 | 药学 | 博客  
 点击次数:

会议专家简介:管忠震教授

转载请注明来自丁香园
发布日期:2009-10-10 16:20 文章来源:丁香园
分享到: 收藏夹 新浪微博 腾讯微博 开心网 豆瓣社区 人人网
关键词: 管忠震 肿瘤 化疗   点击次数:

Guan Zhongzhen , male, Born in Oct. 1932 at Anhui China. Education: MD Lingnan Univ. Medical School, 1954. Post-doctoral Training on Hematology, Chinese Acad Med. Scis Hematology Inst. 1963; WHO Sponsored Visiting Scholar, M.D. Anderson Hosp & Res Inst, Houston, and was appointed as visiting Assoc Prof, 1982~1983. Appointments: Director of Cancer Hospital, Sun Yat-sen Medical Univ. Guangzhou (1986~1993). Prof & Chief, Medical Oncology Dept. Member of Directors, Chinese National Board of Cancer Management & Research. Chairman, Oncology/Hematology Drug Evaluation Committee, Chinese Ministry of Health. Dir, Chinese Anticancer Assoc & President of Canton Branch. Also:Member of scientific advisory board , IOF; Scientific advisor of cancer Institute, Chinese Univ of Hong Kong. Main interest of Study: Chemotherapy of Lymphomas, Lung Cancer, Breast Cancer, and new anticancer drug development. Contributions to: Chinese J. Intern. Med; Chinese J. of Cancer, J of Res & Clin Oncology; Int J Clin Pharm Res.etc.

P.I of many domestic and imported anticancer drugs including Vinorebin, Vindesine,THP-Doxorubicin, Ifosfamide, Lobaplatin,Nedaplatin,Gemcitabine,Docetaxel,10-Hydroxy-Camptothecin,Irinotecan,Oxaliplatin,Topotecan,Gefitinib etc. Also participating many international multicentric studies including HERA trial, Gemzar in Liver Cancer, Topotecan for 2nd line NSCLC. Topotecan /DDP vs Etoposide/DDP in 1st line SCLC, Gefetinib in Chinese pts of NSCLC, IPASS study, Lapatinib in Breast Ca including 1st line HER2 (+) pts and ALLTO trial, TEACH trial, Sorafenib in HCC, etc.

Dr GUAN is one of the pioneers of medical oncology in China. He was recipient of distinguished teachership from the Guangdong Provincial government and also award from Sun Yat-sen University, ACOS and Chinese Anticancer Association.

编辑: ludongcn 作者:丁香园通讯员

以下网友留言只代表网友个人观点,不代表网站观点